Limits...
Ufasomes Mediated Cutaneous Delivery of Dexamethasone: Formulation and Evaluation of Anti-Inflammatory Activity by Carrageenin-Induced Rat Paw Edema Model.

Mittal R, Sharma A, Arora S - J Pharm (Cairo) (2012)

Bottom Line: The transdermal permeation and skin partitioning of from optimized formulation was significantly higher (P < 0.05) as compared to plain drug and plain gel formulation which is due to presence of surfactant acting as permeation enhancer.Permeation of optimized formulation was found to be about 4.7 times higher than plain drug gel.Significant reduction of edema (P < 0.10) was observed in comparison to the commercial product.

View Article: PubMed Central - PubMed

Affiliation: Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India.

ABSTRACT
The purpose of study is to formulate and evaluate ufasomal gel of dexamethasone. Ufasomal suspension was made by sonication method using different concentrations of Span 80, Span 20 and cholesterol along with 25 mg of drug. Ufasomal gel was formulated by hydration method using carbopol 940. Ufasomal vesicles appeared as spherical and multilamellar under Transmission Electron Microscope. Ufasomal formulation prepared with drug to oleic acid molar ratio 8:2 (UF-2) produced greater number of vesicles and greater entrapment efficiency. UF-2 was optimized for further evaluation. The transdermal permeation and skin partitioning of from optimized formulation was significantly higher (P < 0.05) as compared to plain drug and plain gel formulation which is due to presence of surfactant acting as permeation enhancer. Permeation of optimized formulation was found to be about 4.7 times higher than plain drug gel. Anti-inflammatory activity evaluated by inhibition Carrageenan induced rat paw edema model. Significant reduction of edema (P < 0.10) was observed in comparison to the commercial product. Hence oleic acid based vesicles can be used as alternate carrier for topical delivery.

No MeSH data available.


Related in: MedlinePlus

Increase in edema volume (%) in anti-inflammatory activity evaluation of ufasomes containing dexamethasone (0.5% w/w), plain gel “and” marketed formulation using the method of acute edema inhibition produced by carrageenin injection (5 rats per group) (ANOVA, F test).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4595971&req=5

fig9: Increase in edema volume (%) in anti-inflammatory activity evaluation of ufasomes containing dexamethasone (0.5% w/w), plain gel “and” marketed formulation using the method of acute edema inhibition produced by carrageenin injection (5 rats per group) (ANOVA, F test).

Mentions: Due to the best results observed in the physicochemical characterization, UF-2 formulation was chosen to undergo the pharmacological studies. Figure 9 shows the increase in edema volume (%) using the method of acute edema inhibition produced by carrageenin injection, as a function of time. The evaluation of the anti-inflammatory activities was performed by the comparison of UF-2 with a dexamethasone commercial injection product (Decadron) used as reference. When dexamethasone was associated with fatty acid vesicles and its anti-inflammatory activity evaluated by inhibition, carrageenan edema a significant reduction of edema (P < 0.10) was measured in comparison to the commercial product.


Ufasomes Mediated Cutaneous Delivery of Dexamethasone: Formulation and Evaluation of Anti-Inflammatory Activity by Carrageenin-Induced Rat Paw Edema Model.

Mittal R, Sharma A, Arora S - J Pharm (Cairo) (2012)

Increase in edema volume (%) in anti-inflammatory activity evaluation of ufasomes containing dexamethasone (0.5% w/w), plain gel “and” marketed formulation using the method of acute edema inhibition produced by carrageenin injection (5 rats per group) (ANOVA, F test).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4595971&req=5

fig9: Increase in edema volume (%) in anti-inflammatory activity evaluation of ufasomes containing dexamethasone (0.5% w/w), plain gel “and” marketed formulation using the method of acute edema inhibition produced by carrageenin injection (5 rats per group) (ANOVA, F test).
Mentions: Due to the best results observed in the physicochemical characterization, UF-2 formulation was chosen to undergo the pharmacological studies. Figure 9 shows the increase in edema volume (%) using the method of acute edema inhibition produced by carrageenin injection, as a function of time. The evaluation of the anti-inflammatory activities was performed by the comparison of UF-2 with a dexamethasone commercial injection product (Decadron) used as reference. When dexamethasone was associated with fatty acid vesicles and its anti-inflammatory activity evaluated by inhibition, carrageenan edema a significant reduction of edema (P < 0.10) was measured in comparison to the commercial product.

Bottom Line: The transdermal permeation and skin partitioning of from optimized formulation was significantly higher (P < 0.05) as compared to plain drug and plain gel formulation which is due to presence of surfactant acting as permeation enhancer.Permeation of optimized formulation was found to be about 4.7 times higher than plain drug gel.Significant reduction of edema (P < 0.10) was observed in comparison to the commercial product.

View Article: PubMed Central - PubMed

Affiliation: Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India.

ABSTRACT
The purpose of study is to formulate and evaluate ufasomal gel of dexamethasone. Ufasomal suspension was made by sonication method using different concentrations of Span 80, Span 20 and cholesterol along with 25 mg of drug. Ufasomal gel was formulated by hydration method using carbopol 940. Ufasomal vesicles appeared as spherical and multilamellar under Transmission Electron Microscope. Ufasomal formulation prepared with drug to oleic acid molar ratio 8:2 (UF-2) produced greater number of vesicles and greater entrapment efficiency. UF-2 was optimized for further evaluation. The transdermal permeation and skin partitioning of from optimized formulation was significantly higher (P < 0.05) as compared to plain drug and plain gel formulation which is due to presence of surfactant acting as permeation enhancer. Permeation of optimized formulation was found to be about 4.7 times higher than plain drug gel. Anti-inflammatory activity evaluated by inhibition Carrageenan induced rat paw edema model. Significant reduction of edema (P < 0.10) was observed in comparison to the commercial product. Hence oleic acid based vesicles can be used as alternate carrier for topical delivery.

No MeSH data available.


Related in: MedlinePlus